Microbiology

Leucomycin A8 is an antibiotic derived from Streptomyces kitasatoensis, exhibiting significant antibacterial activity against a range of Gram-positive bacteria. This compound is primarily employed in infection research, contributing to studies on antimicrobial resistance and the development of new therapeutic agents. Its unique mechanism of action makes it a valuable tool for exploring bacterial protein synthesis inhibition.

DA 1131 is an anionic Carbapenem antibiotic that exhibits a broad spectrum of antibacterial activity against both gram-positive and gram-negative organisms. Its unique structure renders DA 1131 resistant to degradation by various types of β-lactamases, making it a valuable tool in the study of antibiotic resistance and the treatment of bacterial infections. This compound is particularly useful in pharmacological research aimed at developing effective therapies against resistant bacterial strains.

Antibacterial Agent 128 is an innovative siderophore analog-Ciprofloxacin conjugate featuring a cleavable linker. This compound exhibits potent antibacterial activity against Pseudomonas aeruginosa, with minimum inhibitory concentration (MIC) values ranging from 0.25 to 64 μg/mL, and against Burkholderia pseudomallei, with MIC values between 1 and 32 μg/mL. Antibacterial Agent 128 is suitable for research applications focused on combating bacterial infections and studying antibiotic resistance mechanisms.

Cefetamet sodium is a cephalosporin antibiotic that acts primarily by binding to bacterial penicillin-binding proteins (PBPs), disrupting cell wall synthesis. This compound exhibits substantial antibacterial activity against both Gram-negative bacteria, including Enterobacteriaceae, Neisseria species, and Haemophilus influenzae, and Gram-positive bacteria such as Streptococcus. Additionally, Cefetamet sodium is effective in lysing Treponema pallidum. It is utilized in research focused on infections of the respiratory tract, urinary tract, and ear, nose, and throat, as well as in studies related to syphilis.

Mycinamicin III is an ester peptide antibiotic that demonstrates activity against Gram-positive bacteria. Its mechanism of action involves inhibiting protein synthesis, making it valuable for research applications in studying bacterial resistance and antibiotic efficacy. Mycinamicin III is useful in the development of new antibacterial agents and for investigating microbial interactions.

Lactaroviolin is an aromatic derivative antibiotic that primarily targets bacterial cell growth. It exhibits inhibitory activity against Mycobacterium tuberculosis, although its efficacy may be modest. This compound serves as a valuable tool for research in the development of novel antimicrobial strategies and understanding antibiotic resistance mechanisms in mycobacterial species.

Pneumocandin A3 is a lipopeptide antibiotic that primarily targets fungal cell wall biosynthesis. It exhibits potent anti-Candida activity, effectively inhibiting 1,3-β-glucan synthesis in vitro, with an IC50 range of 0.07-0.5 μg/mL. This compound is vital for research applications focused on antifungal drug development and the investigation of fungal resistance mechanisms.

Spectinomycin sulfate is an aminocyclitol aminoglycoside antibiotic that targets bacterial protein synthesis, derived from Streptomyces spectabilis. It exhibits bacteriostatic activity, making it effective against various bacterial infections. This compound is primarily utilized in microbiological research and clinical applications to study antibiotic resistance and the mechanisms of bacterial cell growth inhibition.

SCH 34343 is a penem antibiotic that demonstrates potent antibacterial activity against Streptococcus pneumoniae, with a minimum inhibitory concentration (MIC50) of ≤ 0.015 mg/L. It exhibits similar efficacy against viridans streptococci and multiple groups of streptococci, including A, B, C, and G, with MIC50 values ranging from 0.03 to 0.06 mg/L. This compound is suitable for antibacterial research, providing valuable insights into antibiotic efficacy and resistance mechanisms.

Pluraflavin A is an antitumor antibiotic that primarily functions by inhibiting the transcription of the glucose-6-phosphatase gene. This compound exhibits significant anti-proliferative activity against tumor cells, making it a valuable tool for cancer research. Its mechanism of action positions it as a candidate for studies focused on tumor biology and potential therapeutic interventions.

Guamecycline is a semisynthetic tetracycline that targets bacterial ribosomes to inhibit protein synthesis. It exhibits a broad spectrum of antibacterial activity comparable to that of tetracycline. This compound is utilized in research applications involving microbial resistance studies, particularly in understanding the mechanisms of antibiotic efficacy and in developing novel antimicrobial therapies.

KKL-40 is a small molecule inhibitor that targets the trans-transcription process in bacteria. It exhibits effective antibacterial activity against methicillin-sensitive and -resistant Staphylococcus aureus, as well as other Gram-positive pathogens including vancomycin-resistant Enterococcus faecium, Bacillus subtilis, and Streptococcus pyogenes. KKL-40 demonstrates a synergistic effect with the human antimicrobial peptide LL-37 against S. aureus, while showing no synergy with commonly used antibiotics such as daptomycin, kanamycin, or erythromycin. Notably, KKL-40 selectively inhibits trans-transcription without toxicity to HeLa cells, making it a valuable tool for research in bacterial genetics and antibiotic resistance.

11-Deacetoxywortmannin is an antibiotic that targets fungal pathogens, derived from Aspergillus janus and Penicillium funiculosum. It exhibits potent antifungal and anti-inflammatory properties, making it valuable in research focused on managing fungal infections and inflammatory conditions. Additionally, its anti-edema effects contribute to its potential therapeutic applications in various biomedical studies.

Monamycin H1 is an ester peptide antibiotic that primarily targets Gram-positive bacteria. It exhibits potent antimicrobial activity, making it a valuable resource for research applications focused on bacterial infections and resistance mechanisms. Monamycin H1 can be utilized in studies investigating antibiotic efficacy and developmental pharmacology.

1-Deamino-1-hydroxygentamicin C1a is an aminoglycoside antibiotic that exhibits potent activity against both Gram-positive and Gram-negative bacteria. This compound functions by inhibiting bacterial protein synthesis, making it a valuable tool for studying bacterial resistance mechanisms and antibiotic efficacy. Its antimicrobial properties make it suitable for research applications focusing on infectious diseases and antibiotic development.

Viomycin is a potent antibiotic specifically targeting Mycobacteria. It acts by rapidly inhibiting polypeptide chain elongation during protein synthesis in bacterial ribosomes, particularly within purified Escherichia coli polysomes. Viomycin is primarily utilized in research focused on mycobacterial infections and the mechanisms of antibiotic resistance.

Mureidomycin D is an antibiotic that exhibits potent activity against Pseudomonas aeruginosa. This compound targets bacterial cell wall synthesis, disrupting the growth of pathogenic strains. Mureidomycin D is utilized in research applications focused on combating antibiotic-resistant infections and studying the mechanisms of bacterial resistance.

Endophenazine D is a phenazine antibiotic that exerts its antimicrobial effects through interference with DNA synthesis and cellular respiration. This compound demonstrates significant activity against a range of bacterial strains, making it an important tool in microbiological research. Its applications include studying antibiotic resistance mechanisms and evaluating potential therapeutic strategies in infectious disease models.

Cefluprenam is a β-lactam antibiotic that targets bacterial cell wall synthesis, exhibiting broad-spectrum antibacterial activity. This compound is effective against a range of Gram-positive and Gram-negative organisms, making it suitable for research in antibiotic resistance and bacterial infection studies. Cefluprenam serves as a valuable tool in microbiological applications aimed at understanding and combating bacterial pathogens.

Clindamycin palmitate is an antibacterial agent that undergoes rapid hydrolysis in vivo, converting to the active form, clindamycin, which effectively targets bacterial infections. This prodrug is primarily used in research to study antibiotic efficacy and mechanisms of action. Its application extends to exploring resistance patterns and enhancing the understanding of bacterial pathogenesis.

Lipohexin is a peptide antibiotic that targets Gram-positive bacteria. It exhibits significant antibacterial activity, as evidenced by its competitive inhibition of human placental proline endopeptidase, with an IC50 of 3.5 μM. Additionally, Lipohexin inhibits proline endopeptidase from Flavobacterium meningoseptica, with an IC50 of 25 μM, making it a valuable reagent for research in antibiotic development and enzyme inhibition studies.

Arylomycin B7 is a lipohexapeptide antibiotic that targets Gram-positive bacteria. It exhibits potent antibacterial activity by inhibiting bacterial protein synthesis. This compound is valuable for research into antibiotic mechanisms and the development of new therapeutic agents against resistant pathogens.

Dynemicin O is an antibiotic that exerts potent activity against Gram-positive bacteria. Its mechanism involves disruption of bacterial DNA synthesis, making it a valuable tool for studying bacterial resistance and efficacy in antibiotic development. Researchers can utilize Dynemicin O in microbiological studies to better understand the therapeutic potential and limitations of antimicrobial agents.

Napsamycin B is an antibiotic known for its selective antibacterial activity against Pseudomonas aeruginosa and various other Pseudomonas species. While it demonstrates limited effectiveness against other Gram-positive and Gram-negative bacteria, Napsamycin B's specificity makes it a valuable reagent for studying Pseudomonas infections and exploring antibiotic mechanisms in related research applications.

Clindamycin B is a derivative of Clindamycin, primarily targeting parasitic infections. It exhibits potent inhibitory activity against various protozoa, making it useful in research related to parasitic diseases. Clindamycin B is valuable for studying mechanisms of action in parasite biology and evaluating therapeutic strategies for parasitic infections.

3-O-Demethyl-2'-N-glylfortimicin B is an aminoglycoside antibiotic that primarily targets bacterial ribosomes, inhibiting protein synthesis. This compound exhibits broad-spectrum antibacterial activity, making it valuable in research applications aimed at studying bacterial resistance mechanisms and the pharmacodynamics of aminoglycoside antibiotics. Its unique structural modifications further enhance its stability and efficacy against various pathogenic strains.

Argimicin B is an antibiotic derived from Sphingomonas sp., exhibiting potent algicidal activity against various toxic cyanobacteria. With a minimum inhibitory concentration (MIC) in the low micromolar range, it serves as an effective agent for studying cyanobacterial blooms and their ecological impacts. Its unique mode of action makes Argimicin B a valuable tool in environmental microbiology and phytoplankton research applications.

Dynemicin P is a potent antibiotic primarily targeting bacterial cell wall synthesis. It exhibits significant antibacterial activity, making it valuable for research applications focused on studying gram-positive bacterial infections. Its unique mechanism of action provides insights into antibiotic resistance and the development of new therapeutic strategies.

Pacidamycin D is an antibiotic that specifically targets Pseudomonas aeruginosa. It exhibits antimicrobial activity with a minimum inhibitory concentration (MIC) ranging from 4 to 16 μg/mL against this strain. However, it shows no efficacy against other Gram-negative and Gram-positive bacteria, including drug-resistant variants of Pseudomonas aeruginosa. This compound is useful for research applications focused on bacterial resistance mechanisms and the development of targeted antibiotic therapies.

1-Deamino-1-hydroxygentamicin C2 is an aminoglycoside antibiotic that targets bacterial ribosomes to inhibit protein synthesis. This compound exhibits antibacterial activity against both Gram-positive and Gram-negative bacteria, making it valuable in microbiological research. It is utilized in studies investigating antibiotic resistance and evaluating therapeutic efficacy in bacterial infections.

Antibiotic Adjuvant 3 is a potent colistin-potentiating agent that enhances the efficacy of antibiotics against resistant strains. This compound demonstrates a minimum re-sensitizing concentration of 0.25 μg/mL against Escherichia coli AR-0493, while maintaining low toxicity in mammalian systems. It is particularly valuable in research applications focused on combating antibiotic resistance and improving therapeutic outcomes.

Cefmenoxime sodium is a semisynthetic cephalosporin antibiotic that targets bacterial cell wall synthesis. It exhibits antibacterial activity against a broad spectrum of both gram-positive and gram-negative bacteria. This compound is primarily utilized in microbiological studies and therapeutic applications to combat bacterial infections.

Leucomycin U is a macrolide antibiotic targeting bacterial protein synthesis. This compound exhibits potent activity against Gram-positive bacteria and also shows efficacy against spirochetes, Rickettsia, and Chlamydia. It is suitable for use in microbial research and the study of bacterial resistance mechanisms.

Mannosyl glucosaminide is an aminoglycoside antibiotic that targets bacterial ribosomes, disrupting protein synthesis. It exhibits antibacterial activity against various strains, including mycobacteria and yeast, making it valuable for research in antimicrobial treatments. This compound can be applied in studies investigating the mechanisms of antibiotic resistance and the development of new therapeutic strategies.

Dioxolamycin is an antitumor antibiotic that selectively targets cancer cell activity, particularly in L-1210 cells. It demonstrates significant cytotoxic effects, making it a valuable tool in cancer research and the development of novel therapeutic strategies. Its mechanism of action involves interfering with cellular processes essential for tumor growth and survival, positioning it as a critical compound in the study of antitumor agents.

Katanosin A is a peptide antibiotic that targets Gram-positive bacteria. It exhibits potent antimicrobial activity, making it a valuable tool for research in the study of antibiotic resistance mechanisms and the development of new antimicrobial therapies. Katanosin A is particularly useful in exploring the efficacy of peptide-based antibiotics in clinical applications.

Epithienamycin D is a carbapenem antibiotic that exhibits broad-spectrum antibacterial activity. It is effective against both Gram-positive and Gram-negative bacteria, making it a valuable tool in microbiological research. This compound can be utilized in studies focused on antibiotic resistance and the development of new antimicrobial therapies.

Macquarimicin A is a potent antibiotic known for its ability to inhibit bacterial growth. It demonstrates significant antimicrobial activity against a range of gram-positive and some gram-negative bacteria. This compound is primarily utilized in microbiological research to study antibiotic resistance mechanisms and the effects of antibiotic treatment. Its unique structure and mode of action make Macquarimicin A an important tool for exploring and developing new therapeutic strategies in infectious disease research.

Pristinamycin IIC is an ester peptide antibiotic targeting Gram-positive bacteria. It exhibits potent antibacterial activity against a range of pathogenic strains, making it valuable in studies related to antibiotic resistance and bacterial infections. Research applications include in vitro susceptibility testing and the evaluation of antibiotic efficacy in various clinical scenarios.

Saquayamycin B is an angucycline antibiotic known for its potent antitumor activity. It exhibits significant inhibition against human lung (H-460) and breast cancer (MCF-7) cell lines, demonstrating GI50 values of 12.2 µM and 15.2 µM, respectively. This compound is a valuable tool for research in cancer therapeutics and antibiotic development.

Phleomycin G is a heteropeptide antibiotic that primarily targets bacterial ribosomes. It exhibits potent activity against Gram-positive and some Gram-negative bacteria, as well as mycobacteria. Research indicates that Phleomycin G can prolong the survival of mice with Ehrman's ascites carcinoma and has demonstrated inhibitory effects on various carcinoma types in murine models. This compound is valuable for studies involving bacterial infections and cancer therapeutics.

Pluracidomycin A1 is a carbapenem antibiotic that targets bacterial cell wall synthesis. It exhibits potent activity against both Gram-positive and Gram-negative bacteria while effectively inhibiting β-lactamase enzymes. This makes it a valuable reagent for research focused on antibiotic resistance and the mechanisms of bacterial pathogenicity.

YM 133 is a semisynthetic macrolide antibiotic that exerts potent bactericidal activity. It demonstrates effectiveness against Erythromycin, Josamycin, and Rokitamycin-resistant strains of staphylococci, streptococci, Bacteroides spp., and Clostridium spp., showcasing strong activity against macrolide-resistant bacteria and anaerobic pathogens. This compound is valuable for antibacterial research focusing on resistant infections and macrolide antibiotic efficacy.

Arylomycin B1 is a lipohexapeptide antibiotic targeting Gram-positive bacteria through inhibition of bacterial signal peptidase. It exhibits potent antibacterial activity and serves as a valuable research tool for studying bacterial resistance mechanisms and the development of novel antibiotic therapies. This compound is essential for investigations in microbiology and antibiotic efficacy.

Nafithromycin is an orally available antibiotic that primarily targets bacterial pathogens, effectively inhibiting strains responsible for community-acquired pneumonia, including Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and methicillin-susceptible Staphylococcus aureus. This compound exhibits a minimum inhibitory concentration (MIC90) of 0.12 mg/liter against macrolide-resistant and telithromycin-insensitive strains of Streptococcus pneumoniae. Nafithromycin is useful in research applications focused on antibiotic resistance and the treatment of respiratory infections.

Hydroxymycotrienin B is an Ansa antibiotic with potent antitumor activity. It effectively inhibits the proliferation of human neck tumor cell lines, demonstrating a stronger inhibitory effect on HPV gene positive cells, such as HeLa, CaSKi, and SiHa, compared to HPV gene negative cells. This compound is of significant interest in cancer research and the development of targeted therapies against HPV-associated malignancies.

Kocurin is a thiazolyl cyclic-peptide antibiotic that primarily targets bacterial protein biosynthesis during the translation phase. It exhibits strong antibacterial activity against Gram-positive bacteria, making it a valuable reagent for research into antimicrobial resistance and the mechanisms of bacterial translation. Kocurin shows no activity against fungi or Gram-negative bacteria, highlighting its selective antibacterial profile.

Griseusin A is a quinone-based antibiotic that primarily targets Gram-positive bacteria. This compound exhibits significant antibacterial activity, making it a valuable tool in the study of bacterial infections and resistance mechanisms. Griseusin A's unique mechanism may provide insights into novel therapeutic approaches for treating Gram-positive bacterial infections.

Rifamexil is an antibiotic derivative of Rifamycin, specifically designed to inhibit bacterial RNA polymerase. It demonstrates effective activity against Mycobacterium avium complex and various other mycobacterial strains. This reagent is valuable for research applications focused on antimicrobial resistance and the development of treatments for mycobacterial infections.

Y-05460M-A is a substituted isocoumarin antibiotic that demonstrates inhibitory activity against both Gram-positive and Gram-negative bacterial strains. Additionally, Y-05460M-A exhibits cytotoxic effects against P388 lymphatic leukemia cells and has been shown to possess antiulcer activity. This compound is a one-carbon lower homologue of PM-04128 and can be synthesized from N-Boc-L-valine, making it a valuable reagent for antimicrobial and anticancer research.